Thoracic PDX (MSK, Provisional)

Summary

Thoracic PDX (MSK, Provisional) is a study catalogued by cBioPortal DataHub under the cancer-type code lung. EvidenceHelix groups it with multiple or not classified from the title studies.

Study description

Targeted sequencing of thoracic PDX lines to characterize genetic alterations in 318 tumor/normal pairs via MSK-IMPACT. This cohort is a PDX tracker of all lung cancer PDX generated at MSK that have been through IMPACT sequencing. This is a live datafeed, increasing over time, not published as a cohort.

Text as published in the source's study metadata.

Citation & PubMed

The source lists no citation or PubMed id for this study.

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

lung_msk_pdx

Short name

MIXED (CMO CR_pdx IMPACT)

Source cancer-type code

lung

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

The source lists no citation or PubMed id for this study.

Related studies

• Thoracic Cancer (MSK, Nat Commun 2021)

  Targeted sequencing of tumor and PDX thoracic samples.

  Multiple or not classified from the titleMSK studiesSource code lungPubMed 1

• Appendiceal Cancer (MSK, J Clin Oncol 2022)

  Targeted sequencing of 273 appendiceal tumor/normal pairs via MSK-IMPACT platform.

  Multiple or not classified from the titleMSK studiesSource code apadPubMed 1

• BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is comple…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)

  Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)

  Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)

  Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)

  Targeted sequencing of 1,007 cerebrospinal fluid circulating tumor DNA from patients with central nervous system tumors using MSK-IMPACT and their matched normals.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.